Optometrists best placed to screen population

Article

Although almost a third of patients referred by optometrists do not have glaucoma, optometrists are still best placed to screen the UK population for glaucoma, according to Dr Aye and colleagues from Northampton General Hospital, UK.

Although almost a third of patients referred by optometrists do not have glaucoma, optometrists are still best placed to screen the UK population for glaucoma, according to Dr Aye and colleagues from Northampton General Hospital, UK.

A study was conducted to review the glaucoma data provided by optometrists on referral forms. A total of 78 referrals were received over a five-month period. The most common reasons for referral were elevated IOP (59%), optic disc abnormalities (45%), visual field defects (14%) and other abnormalities (12%).

A total of 68% of forms were incomplete, missing vital data. Of the IOP measurements, 38% were within 2 mmHg of IOP obtained with Goldmann tonometry and 34% of pneumatonometry readings differed by more than 5 mmHg with that obtained by applanation tonometry. Twenty-seven percent of patients were found not to have glaucoma and were discharged, while 26% of patients were started on treatment.

According to the investigators, despite varying IOP measurements, optometrists are still best placed to screen the UK population for glaucoma.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.